Pulse nav.journalClub Aktive Debatten Trends Entdecken Forschende

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Start Entdecken nav.journalClub Trends

⌘+K

Depot Extracts for Venom Immunotherapy: A Delphi Consensus on Safety and Efficacy | Synapse

March 13, 2026

Depot Extracts for Venom Immunotherapy: A Delphi Consensus on Safety and Efficacy

Key Points

The aim is to assess the safety and efficacy of Depot Venom Immunotherapy (dVIT).
Consensus reached through a Delphi method involving experts in immunotherapy.
Comparison of dVIT safety with aqueous venom immunotherapy protocols.
Evaluation of immunological enhancements with dVIT.
dVIT safety is comparable to aqueous venom immunotherapy.
Immunological specific enhancements were identified, indicating potential benefits.

Abstract

Summary A Delphi consensus, funded by an immunotherapy manufacturer, was reached on Depot Venom Immunotherapy (dVIT). dVIT safety is similar to aqueous VIT (rush and ultra‐rush protocols), with immunological specific enhancements.

KI fragen

Like

Bookmark

Share

Cite This Study

Pravettoni et al. (Tue,) studied this question.

synapsesocial.com/papers/69b3ac9002a1e69014cce6ca https://doi.org/https://doi.org/10.1111/cea.70278

KI fragen

Like

Bookmark

Share